Worm.com

Guide to Spyware and AntiVirus Information

You are currently browsing the Worm.com weblog archives for the day Wednesday, September 19th, 2007.

 

September 2007
M T W T F S S
« Aug   Oct »
 12
3456789
10111213141516
17181920212223
24252627282930

Sponsors

Archive for September 19th, 2007

JOHANNESBURG, South Africa — International medical personnel and supplies are being airlifted to a remote region of central Congo to combat what threatens to become the world’s most serious outbreak of the deadly Ebola virus in years.

Only nine cases of the disease have been confirmed by laboratory tests. But medical authorities suspect the virus has killed 168 people and sickened 375 others across a heavily forested region where villages are linked only by deeply rutted dirt roads. Health officials say it’s possible that new cases will continue to emerge in the coming months.

“It’s a serious outbreak,” said Peter Kilmarx, an official with the U.S. Centers for Disease Control and Prevention who toured the area last weekend. “Every day, there is a new town with a reported suspect case.”

The epicenter of the outbreak, which is serviced by a single dirt- and-grass airstrip, consists of three towns in Congo’s Kasai Occidental province, but the affected area appears to stretch for more than 100 miles.

Kilmarx, who was speaking from the Congolese capital of Kinshasa, said that one village market he visited had been abandoned and that many Congolese in the area appeared reluctant to shake hands for fear of contracting the highly contagious disease.

Efforts to control Ebola depend on identifying and isolating those already infected. There is no cure, and most who contract the virus die. The disease typically produces acute flu-like symptoms, such as high fever, headaches and diarrhea. Hemorrhaging also is common, and bodily fluids containing the virus are the main source of transmission.

“The only thing you can do is isolate the patient and avoid other infections,” said Josep Prior, the top official with Doctors Without Borders in Congo, speaking from Kinshasa. “It’s quite shocking. ”

The international medical aid group has taken the lead in a global response that also includes the World Health Organization and the U.S. team. These groups are assisting Congolese medical authorities in tracking the path of the disease, alerting the public and caring for the ill.

Doctors Without Borders has converted a mud-walled building with a tin roof into a 15-bed isolation ward. To prevent infection, members of medical teams wear protective suits along with surgical masks, gloves and boots. Orange plastic fencing, stretched between tree branches pounded into the ground, keeps potential onlookers away.

As doctors around the region report suspected new cases, medical teams are preparing to visit villages by car and motorbike in search of people with symptoms. That process may yield many more cases, and two mobile laboratories being flown to the area will speed the process of confirming cases.

Anyone who had contact with an infected person is supposed to be identified, but the logistics are daunting in an area where roadways are so damaged by war and neglect that a trip of only several miles can take an hour.

Doctors Without Borders also is assisting Congolese authorities in attempting to keep medical facilities open.

Gregory Hartl, a WHO spokesman, said other diseases, including typhoid, malaria and shigella, may be responsible for some of the deaths now suspected of being caused by Ebola. Reports of suspicious deaths date back to April. WHO also has called for international help to control the outbreak.

Cases of Ebola have been reported during the past decade in Congo, Sudan, Uganda, Gabon and South Africa. The outbreak in Congo in 2003 killed 128 people; a previous outbreak there in 1995 killed 250.

c2007 ANG Newspapers. Cannot be used or repurposed without prior
written permission.
Provided by ProQuest Information and Learning Company. All rights Reserved.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

Funding Part of Bioterrorism Response Development Effort

PORTLAND, Ore. — AVI BioPharma, Inc. (Nasdaq:AVII) today announced receipt of a $2.66 million contract for development of a therapeutic NEUGENE([R]) antisense drug targeting dengue virus infections. This is the fourth contract related to an $11 million allocation for defense-related development of therapeutic antisense drugs, part of the 2006 Defense Appropriations Act. Under the four contracts, AVI anticipates receiving up to $9.8 million, net of government administrative costs.

In May 2007, AVI announced that it had received the first three signed contracts valued at approximately $7.1 million from the Department of Defense (DoD) for the development of therapeutic drugs targeting Ebola virus infections, Marburg virus infections and exposure to Bacillus anthracis (anthrax) and Ricin toxins.

"Taken as a whole, the research funded by these four contracts is meant to improve our national biodefense preparedness," said Alan P. Timmins, president and COO of AVI. "In addition, the research will increase our collective understanding of and potential response options to deadly viruses that still occur naturally outside the United States. Previous studies have shown that NEUGENE([R]) antisense therapeutics may be a viable approach to treating victims exposed to these potentially lethal viruses and toxins."

Last week the company announced the presentation of successful preclinical results in Ebola virus and in Marburg virus. That research was supported by a separate $28 million research contract with the Defense Threat Reduction Agency, an agency of the DoD.

NEUGENE antisense compounds are synthetic polymers that mirror a critical portion of a disease-causing organism’s genetic code, which bind to specific portions of the target genetic sequence. Like a key in a lock, NEUGENE compounds are designed to match up perfectly with a specific gene or pathogen sequence, blocking the function of the target gene or pathogen.

About Dengue Virus</p>

Dengue and dengue hemorrhagic fever are caused by one of four closely related virus serotypes. Like the Ebola virus, Dengue virus is a member of the flavivirus family. Dengue is one of the most important mosquito-borne viral disease affecting humans; its global distribution is comparable to that of malaria, and an estimated 2.5 billion people live in areas at risk for epidemic transmission (CDC, Dengue fever fact sheet). Each year, tens of millions of cases of Dengue fever occur and, depending on the year, up to hundreds of thousands of cases of Dengue hemorrhagic fever. The case-fatality rate of Dengue hemorrhagic fever in most countries is about 5 percent, but this can be reduced to less than 1 percent with proper treatment. Most fatal cases are among children and young adults.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI’s lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI’s antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including dengue virus, Ebola virus and H5N1 avian influenza virus. AVI’s NEUGENE-based ESPRIT technology is initially being applied to potential treatments for Duchenne muscular dystrophy. More information about AVI is available on the company’s Web site at http://www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.

COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis